At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Closed The day following Ching Ming Festival 04-02 16:08:21
91.500
+0.600
+0.66%
High92.250Low88.700Vol14.72M
Open90.950D1 Closing90.900Amplitude3.91%
Mkt Cap158.75BTradable Cap158.75BTotal Shares1.74B
T/O1.34BT/O Rate0.85%Tradable Shares1.74B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Business Travelers Can Now Earn Rewards Points for Hotel Stays, Industry Explores Innovative Approach
Deep News  ·  04-01
Business Travelers Can Now Earn Rewards Points for Hotel Stays, Industry Explores Innovative Approach
INNOVENT BIO Grants 1.94 Million Share Options and 10.24 Million Restricted Shares
Stock News  ·  03-31
INNOVENT BIO Grants 1.94 Million Share Options and 10.24 Million Restricted Shares
Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial
Reuters  ·  03-31
Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial
Innovent's Partner Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of Ibi324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
THOMSON REUTERS  ·  03-31
Innovent's Partner Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of Ibi324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Innovent Biologics grants 10.2 million restricted shares under 2024 share scheme
Reuters  ·  03-31
Innovent Biologics grants 10.2 million restricted shares under 2024 share scheme
A Look At Innovent Biologics (SEHK:1801) Valuation After Recent Share Price Momentum
Simply Wall St.  ·  03-30
A Look At Innovent Biologics (SEHK:1801) Valuation After Recent Share Price Momentum
CICC Maintains Outperform Rating on Innovent Biologics with HK$118.3 Target Price
Stock News  ·  03-30
CICC Maintains Outperform Rating on Innovent Biologics with HK$118.3 Target Price
Innovent Biologics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Simply Wall St.  ·  03-29
Innovent Biologics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Innovent Biologics' First Full-Year Profit Ignites Biotech Rally
Deep News  ·  03-27
Innovent Biologics' First Full-Year Profit Ignites Biotech Rally
Citigroup Raises Target Price for Innovent Biologics to HK$115, Reiterates Buy Rating
Stock News  ·  03-27
Citigroup Raises Target Price for Innovent Biologics to HK$115, Reiterates Buy Rating
BUZZ-Innovent Biologics set for biggest jump in 5 months on FY revenue growth
Reuters  ·  03-27
BUZZ-Innovent Biologics set for biggest jump in 5 months on FY revenue growth
Innovative Drug Stocks Surge as Key Players Trigger Market Frenzy
Deep News  ·  03-27
Innovative Drug Stocks Surge as Key Players Trigger Market Frenzy
Stock Track | INNOVENT BIO Soars 6.05% in Morning Trading on Strong Earnings and First Annual Profit
Stock Track  ·  03-27
Stock Track | INNOVENT BIO Soars 6.05% in Morning Trading on Strong Earnings and First Annual Profit
INNOVENT BIO Shares Surge Over 5% on Strong Earnings and First Annual Profit
Stock News  ·  03-27
INNOVENT BIO Shares Surge Over 5% on Strong Earnings and First Annual Profit
Innovent Biologics Turns to Profit in 2025
MT Newswires Live  ·  03-26
Innovent Biologics Turns to Profit in 2025
Press Release: Innovent Announces 2025 Annual Results and Business Updates
Dow Jones  ·  03-26
Press Release: Innovent Announces 2025 Annual Results and Business Updates
INNOVENT BIO Achieves First Full-Year Profit with 2025 Net Income of 813.6 Million Yuan
Stock News  ·  03-26
INNOVENT BIO Achieves First Full-Year Profit with 2025 Net Income of 813.6 Million Yuan
Innovent Biologics 2025 Results: Revenue Soars 38% to RMB 13.04 Billion, Delivers First Full-Year Profit
Bulletin Express  ·  03-26
Innovent Biologics 2025 Results: Revenue Soars 38% to RMB 13.04 Billion, Delivers First Full-Year Profit
Innovent Biologics FY2025 non-IFRS profit jumps to RMB 1.7 billion; revenue rises 38.4% to RMB 13 billion
Reuters  ·  03-26
Innovent Biologics FY2025 non-IFRS profit jumps to RMB 1.7 billion; revenue rises 38.4% to RMB 13 billion
Innovent Biologics - FY Ifrs Revenue RMB13.04 Bln
THOMSON REUTERS  ·  03-26
Innovent Biologics - FY Ifrs Revenue RMB13.04 Bln

Introduction

Company Name.
INNOVENT BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Issue price:
--